Study says docs favor COI disclosure

Lisa Iezzoni, one of the study's authors
Lisa Iezzoni, one of the study's authors

Most physicians agree that it's important to disclose to patients any financial relationships with drug and device companies.

About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest (COI) to patients. But 35.4% still do not completely agree that they should disclose.

Requiring disclosure of financial ties “could be perceived by physicians as something new and intrusive,” Lisa Iezzoni, a professor at Harvard Medical School and lead author of the study, told MM&M.

The Sunshine Act stipulates that drug and device companies start reporting payments of $10 or more to physicians by March 2013.  But disclosure to patients may not immediately follow. “Physicians who do not support public disclosure might resist communicating this information to inquiring patients,” the study authors note, “or might make these conversations more difficult.”
You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.